Autoinflammatory & rare systemic diseases
Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials
Authors' conclusion
Biologic drugs were effective in achieving ACR response and demonstrated a low adverse event profile in the management of Still's disease.
Study context
- Population
- Paediatric (systemic juvenile idiopathic arthritis (sJIA)) and adult (adult-onset Still's disease (AOSD)) patients with Still's disease
- Participants
- 430 participants9 trials
- Comparison
- Biologic drugs vs placebo
- Outcome
- Primary efficacy: ACR50 response; primary safety: serious adverse events
Methodological detailsSUCRA rankings, multivariate meta-analysis
- SUCRA rankings
- Multivariate meta-analysis
Pooled result
As reported in the abstract
ACR50 response
- All biologic drugs associated with greater odds of ACR50 response vs placebo
- No difference between biologic drugs (multivariate meta-analysis)
- Anakinra ranked most effective by SUCRA
Safety
- No statistically significant association between biologic drugs and serious adverse events
- Anakinra ranked safest by SUCRA
Original publication
Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials. Rheumatology (Oxford). Published 22 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →